Conservative think tank report blasts FDA
October 12, 2011 by MassDevice staff
The Competitive Enterprise Institute, a conservative think tank, blasts the FDA and patient safety advocates for smothering new medical technology and calls for stricter oversight of the federal watchdog agency.
A conservative think tank is taking aim at the FDA's program for reviewing medical devices, accusing the federal watchdog agency and public safety advocates of smothering new medical technology.
The Competitive Enterprise Institute report, "Stifling Medical Device Innovation: A Response to Critics of the FDA's 510(k) Clearance Process," was written by Larry Pilot, a lawyer and pharmacist who helped pioneer the FDA's Office of Medical Devices in the late 1960s and early '70s.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Mobilizing on the back end of a disaster
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
Navigation
NEWS
Medical device tax: Consultant calls offshoring concerns 'horse hockey'
Concerns that the medical device tax will push companies to lay off workers and move operations...
FDA clears OrthoSensor's Verasense knee replacement device
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical wins CE Mark for peripheral catheter
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
Recalls: FDA makes Endologix catheter introducer recall Class I
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
pSivida gains big on buyout rumor
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...
